- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Chiesi begins new trial for carbon minimal inhalers

Chiesi has started a long-term phase III clinical safety trial for the new carbon minimal inhalers platform, replacing the current hydrofluorocarbon propellant with a new, low global warming potential propellant.

Chiesi has already completed two short term clinical trials assessing the safety of the
new propellant1, plus three clinical pharmacology studies on the new carbon minimal
fixed combination of an inhaled corticosteroid (ICS), and a long-acting bronchodilator
(LABA).

These studies collectively provided reassuring evidence of a similar performance
and tolerability of the new formulation, when compared to the current one, for patients
with asthma and COPD. This milestone follows successful completion of similar studies in July 2022 with a fixed triple combination.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death
worldwide, and in 2019 caused 3.23 million deaths2. In the same year, asthma affected
an estimated 262 million people causing 455 000 deaths3.

Many COPD and asthma patients depend on pressurized-Metered Dose Inhalers (pMDIs) for treatment. However, there’s debate about how much current propellants contained in pMDIs contribute to global warming. Efforts are underway to reduce their environmental impact4.

The development of the carbon minimal inhalers platform aims at enabling Chiesi to
reduce emissions related to current products by up to 90% when compared to existing
MDIs. This is a key step in our journey to achieve Net Zero greenhouse gas emissions
by 2035, while preserving asthma and COPD patients’ needs.

Giuseppe Accogli, CEO of Chiesi Group said: “At Chiesi, we strongly believe that patients should not have to bear the responsibility of environmental impact when considering treatment options that affect their health. The conclusion of these additional studies and the start of the phase III trial mark a significant milestone in our development of a new carbon minimal inhalers platform. We are confident that we can deliver carbon minimal solutions to patients without compromising safety, usability or efficacy.”

References

1 Clinical Trials. Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance. Available from: https://clinicaltrials.gov/study/NCT05875025A;
Clinical Trials. Study to Compare the Effects of Two Propellants in Adults With Mild Asthma. Available from: https://clinicaltrials.gov/study/NCT05472662

2 https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD)

3 https://www.who.int/news-room/fact-sheets/detail/asthma

4 Pernigotti D,et al. . Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open Respir Res. 2021 Dec;8(1):e001071. doi: 10.1136/bmjresp-2021-001071. PMID: 34872967; PMCID: PMC8650484.

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription